XTR003 not checked

Sinotau Pharmaceutical Group

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total

What this is

How it works
How it works isn't classified yet
Tested for
Ischemic Cardiomyopathy, Heart Failure
Main trialPhase 2
“This is a prospective, multicenter, randomized, open-label, parallel-controlled Phase IIb study to investigate the diagnostic-prognostic utility of XTR003 Injection integrated with 18F-FDG as an exploratory clinical trial. A total of 40-60 patients will be enrolled and randomized into two study groups as: fasting XTR003/18F-FDG group and glucose-loaded group at a 1:1 ratio. Each group will receive resting myocardial perfusion imaging (MPI) combined with metabolic PET imaging to evaluate myocardial metabolic activity and myocardial viability. Segmental perfusion abnormality, metabolic activity…”In the company’s words, NCT07443696 on ClinicalTrials.gov

Other drugs for Heart Failure

All 42 drugs for Heart Failure

Coming up1

Changes1

Last 90 days

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Dec 2026 PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy
Phase 2Completed 4 Mar 2023 XTR003 PET Radiotracer for the Detection of Viable Myocardium
Phase 1Completed 27 Aug 2021 A Phase I Study to Evaluate XTR003 in Healthy Chinese Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow XTR003

Following is part of Solo: you see every change to XTR003 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in